May 28th 2021
By Tony Hagen
More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.
May 22nd 2021
Prestige BioPharma aims to expand its drug pipeline with a $152 million research and development facility.
May 21st 2021
Biosimilar education can increase physician motivation to prescribe these alternatives to costly originator products, panelists said in a Sandoz/Reuters discussion.
May 18th 2021
The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.
May 15th 2021
Streamlining of biologics license applications (BLAs) in Britain is now official, and in the United States, legislators propose a ratings system to promote biosimilars.
May 13th 2021
A second class of biosimilars that are considered "interchangeable" could set biosimilars back in terms of acceptance, according to Albert Kim, MBA.
May 12th 2021
With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.
When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.
May 11th 2021
After being sued for allegedly stealing adalimumab process information, Alvotech fires back.
May 10th 2021
During a talk at the Medicines for Europe Biosimilar Medicines Conference, US and EU regulators discuss the potential for tailored approach to bring biosimilars to market sooner with less expense and wasted effort.
